ASH: Drug Combo Active in Relapsed Mantle-Cell Lymphoma

By Kelley Luckstein

Half of patients with relapsed or refractory mantle-cell lymphoma achieved major responses when treated with the investigational agent temsirolimus and rituximab (Rituxan), data from an ongoing clinical study showed.

Responses persisted for almost 10 months and demonstrated durability in rituximab-refractory patients, according to Stephen M. Ansell, MD, of the Mayo Clinic in Rochester, Minn.